Polar Capital Biotech R Inc

Performance History30/04/2019
Growth of 1,000 (EUR)
Polar Capital Biotech R Inc
Fund25.2-5.114.30.616.9
+/-Cat5.812.08.39.62.1
+/-Idx0.713.97.54.94.7
 
Key Stats
NAV
23/05/2019
 USD 23.46
Day Change -0.89%
Morningstar Category™ Sector Equity Biotechnology
ISIN IE00B3XLHR60
Fund Size (Mil)
17/05/2019
 USD 516.13
Share Class Size (Mil)
23/05/2019
 USD 184.26
Max Initial Charge 5.00%
Ongoing Charge
18/02/2019
  1.66%
Investment Objective: Polar Capital Biotech R Inc
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation.
Returns
Trailing Returns (EUR)23/05/2019
YTD16.08
3 Years Annualised15.16
5 Years Annualised19.00
10 Years Annualised-
12 Month Yield 0.00
Dividend Paying Frequency Annually
Management
Manager Name
Start Date
David Pinniger
31/10/2013
Inception Date
31/10/2013
Advertisement
Benchmarks
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNo
HedgingNo
OtherNot Specific
Portfolio Profile for  Polar Capital Biotech R Inc31/03/2019
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stocks90.710.0090.71
Bonds0.000.000.00
Cash9.290.009.29
Other0.000.000.00
Top 5 Regions%
United States65.73
Eurozone15.81
Europe - ex Euro6.60
United Kingdom4.34
Asia - Emerging3.97
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Alexion Pharmaceuticals IncHealthcareHealthcare7.96
Regeneron Pharmaceuticals IncHealthcareHealthcare6.45
Incyte CorpHealthcareHealthcare6.25
Vertex Pharmaceuticals IncHealthcareHealthcare5.96
argenx SEHealthcareHealthcare5.46
Polar Capital Biotech R Inc
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)